Gilead Sciences | GILD - Pre Tax Profit

Stock Price
142.40
Daily Change
0.86 0.61%
Monthly
-4.15%
Yearly
40.43%
Q2 Forecast
135.50

Gilead Sciences reported $3.64B in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Agios Pharmaceuticals USD -109.06M 5.62M Dec/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 389.94M 92.37M Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.64B 445M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
United Therapeutics USD 444M 6M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025